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Parkinson’s disease (PD) is a neurodegenerative disorder marked by the selective degeneration of dopaminergic neurons in the
nigrostriatal pathway. Several lines of evidence indicate that mitochondrial dysfunction contributes to its etiology. Other studies
have suggested that alterations in sterol homeostasis correlate with increased risk for PD. Whether these observations are
functionally related is, however, unknown. In this study, we used a toxin-induced mouse model of PD and measured levels of
ninesterolintermediates.Wefoundthatlanosterolissigniﬁcantly(B50%)andspeciﬁcallyreducedinthenigrostriatalregionsof
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice, indicative of altered lanosterol metabolism during PD pathogenesis.
Remarkably, exogenous addition of lanosterol rescued dopaminergic neurons from 1-methyl-4-phenylpyridinium (MPPþ)-
induced cell death in culture. Furthermore, we observed a marked redistribution of lanosterol synthase from the endoplasmic
reticulumto mitochondria in dopaminergic neurons exposedto MPPþ, suggestingthat lanosterolmight exert its survival effect
by regulating mitochondrial function. Consistent with this model, we ﬁnd that lanosterol induces mild depolarization of
mitochondria and promotes autophagy. Collectively, our results highlight a novel sterol-based neuroprotective mechanism with
direct relevance to PD.
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Parkinson’s disease (PD) is a movement disorder marked by
the selective degeneration of dopaminergic neurons in the
nigrostriatal pathway. About 5–10% of PD are genetically
linked with mutations in genes such as leucine-rich repeat
kinase 2 (LRRK2), alpha-synuclein, PTEN-induced putative
kinase 1 (PINK1), Parkin and DJ-1.
1 These genetic PD cases,
while rare, have provided insights into mechanisms of PD
pathogenesis and many of which point toward mitochondrial
dysfunction.
1–3 For example, PINK1, Parkin and DJ-1 control
clearance of mitochondria by mitophagy in response to
cellular stress.
3 Mitochondrial defects are also seen in
idiopathic PD, whereby the catalytic activity of brain mito-
chondrial complex I is compromised.
4 Finally, environmental
toxins that affect complex I, such as 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP),
5 can also induce
Parkinsonism. The active metabolite of MPTP, 1-methyl-4-
phenylpyridinium (MPPþ), selectively enters dopaminergic
neurons via the dopamine transporter, inhibits mitochondrial
complex I and eventually induces clinical symptoms
reminiscent of PD.
As MPTP/MPPþ toxicity emulate PD symptoms, it has
been widely used in animal and cellular models to study
neuronal cell death and to screen for neuroprotective agents.
Of the neuroprotective metabolites identiﬁed, many are found
in mitochondria, including L-carnitine, creatine and coenzyme
Q (CoQ)-10.
6 Although their precise protective mechanisms
are still poorly understood, some evidence suggests that they
act as mitochondrial uncouplers.
7 Consistent with this model,
uncoupling proteins (UCPs) are protective in the MPTP model
ofPD,
8,9andtheirexpressionisdownregulatedinDJ-1knock-
out mice.
10 Neuronal cell death induced by glutamate toxicity
can also be rescued by mitochondrial uncouplers.
11
More recently, misregulation of sterol metabolism has
also been implicated in PD. In clinical studies, elevation of
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www.nature.com/cddlow-density lipoprotein cholesterol (LDL-C) in serum corre-
lates with higher prevalence of PD,
12 whereas higher serum
levels of total cholesterol are associated with a decreased risk
of PD.
13 Biochemical studies showed that alpha-synuclein,
the major component of Lewy bodies found in PD brains,
binds to cholesterol with high afﬁnity,
14 and its aggregation is
accelerated in presence of oxidized cholesterol.
15 In a
separate line of investigation, oxidative stress has been
shown to increase levels of lanosterol, a cholesterol pre-
cursor, in mitochondria and several other intracellular
compartments of macrophages, suggesting that this sterol
metabolite may be part of a global cellular response to
stress.
16 Yet, how sterol metabolism is altered in the brains of
PD patients, or which sterol metabolites, if any, have an
impact on the survival of dopaminergic neurons is unknown.
Our study investigated the role of sterol metabolism in the
MPTP/MPPþ model of PD. Our results provide evidence for
the speciﬁc role of lanosterol as a neuroprotective agent in
dopaminergic neurons. We also show that lanosterol induces
mild uncoupling of mitochondria and promotes autophagy,
two events that have been previously linked to neuroprotec-
tion in various models of PD. To our knowledge, our work
provides the ﬁrst link between sterol metabolism and
mitochondrial function, and identiﬁes lanosterol as a potential
therapeutic agent for PD.
Results
Lanosterol levels are decreased in the striatum and
ventral midbrain of MPTP-injected mice. To determine if
sterol metabolism is altered in a rodent model of PD, we
measured levels of sterol metabolites in the striatum and
ventral midbrain of control and MPTP-treated mice by gas
chromatography-mass spectrometry (GC–MS). This acute
MPTP injection regime results in about 35% loss of
dopaminergic neurons after 48h.
17 Of the nine metabolites
analyzed, we found that lanosterol, the ﬁrst cyclic sterol, was
reduced by B50% in affected areas (Figure 1). Owing to the
speciﬁc and highly signiﬁcant reduction in the levels of
lanosterol in the affected areas of MPTP-treated animals, we
reasoned that lanosterol might be important for dopaminergic
neuronal survival.
Lanosterol protects dopaminergic neurons from MPPþ
-induced cell death. We asked whether exogenous addition
of lanosterol protects dopaminergic neurons against MPPþ-
induced cell death. Primary postnatal neuron cultures from the
ventral midbrain were treated with MPPþ, and the survival of
dopaminergic neurons was determined in the absence or
presence of exogenously added lanosterol. In all, 48% of
dopaminergic neurons survived on treatment with MPPþ
under these culture conditions (Figures 2a and c).
Co-incubation of MPPþ with phosphatidylcholine (PC,
vehicle control) or cholesterol did not improve survival of
dopaminergic neurons (Figures 2b and c). In contrast, co-
treatment of the cultures with MPPþ and lanosterol increased
survival of dopaminergic neurons to 76% (Figures 2b and c).
Thus, lanosterol, but not cholesterol or PC, rescues
dopaminergic neurons from MPPþ-induced cell death.
To determine if addition of lanosterol in culture affects other
sterol intermediates, we analyzed an array of metabolites
(squalene, lanosterol, lathosterol, 7-dehydrocholesterol,
desmosterol, cholesterol, 7-b hydroxycholesterol, 7-keto-
cholesterol and 24-hydroxycholesterol) in extracts from
ventral midbrain cultures by GC–MS. In cells treated with
lanosterol, we observed a 12-fold increase in lanosterol
levels relative to control (no treatment, Figures 2d and e) and
no detectable effect on other sterol metabolites tested
(Figure 2e), suggesting that cells have a high capacity to
accumulate lanosterol, consistent with previous ﬁndings in
macrophages.
16 This is not the case for cholesterol, as we did
not detect any changes in cholesterol levels on exogenous
addition of cholesterol, perhaps because neuronal cholesterol
homeostasis is tightly regulated.
18 In addition to the metabo-
lites indicated above, we also tested the impact of lanosterol
and cholesterol addition on levels of ubiquinones, isoprenoid-
derived electron carriers in mitochondria, and found no
signiﬁcant differences (Figures 3a and b).
In these experiments, postnatal dopaminergic neurons
were grown in direct contact with a glia feeder. It is therefore
possible that neuroprotection is indirectly mediated by a
modiﬁcation of astrocyte physiology. To address whether
lanosterol addition leads to a speciﬁc increase in lanosterol
concentration in neurons, we repeated these experiments
using hippocampal neurons cultured according to Banker’s
method,
19 which allows physical separation of neurons and
astrocytes. We found that lanosterol levels increased in both
neurons and astrocytes to a similar extent on treatment with
exogenous lanosterol (data not shown). Although we cannot
rule out the possible contribution of astrocytes in lanosterol-
mediated neuroprotection, our results indicate that lanosterol
levelsaresigniﬁcantlyelevatedinneurons,arguingforadirect
role of lanosterol in promoting survival of dopaminergic
neurons.
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Figure 1 Lanosterol is the only sterol speciﬁcally depleted in affected brain
areas of mice treated with MPTP. C576B6 mice were treated with the acute
schedule of MPTP injections. At 48h after the last dose of MPTP, the ventral
midbrainandstriatumweredissected,andlipidswereextractedforanalysisofsterol
intermediates by GC–MS. Fold changes are plotted on the y axis, which represent
theaveragelevelsfromMPTP-treatedanimals(n¼4)normalizedtoaveragelevels
from saline-treated (control) animals (n¼6) for each metabolite. Error bars
represent S.E.M. In both brain regions, the levels of lanosterol are reduced
signiﬁcantly in MPTP-treated animals. ***Po0.001
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Cell Death and DifferentiationToexplorethemechanismsunderlyinglanosterol-mediated
neuroprotection, we next investigated the effects of MPPþ
and lanosterol on various signaling pathways previously
implicated in cellular metabolism and neurodegeneration.
First, we examined the expression level of sterol response
element-binding protein (SREBP2, Figure 4a), a transcription
factor reported to exacerbate neuronal degeneration.
20
We found that MPPþ induced a modest increase in
SREBP2 levels, which was not rescued by lanosterol
addition (Figure 4a, top panel). We also checked for levels
of cdk5 activator protein with 35kDa (p35), the activator of
cyclin-dependent kinase 5 (cdk5), because the genetic
ablation of p35/cdk5 confers neuroprotection in the MPTP
model.
21 Although we observed a decrease in p35 levels in
MPPþ-treated cells, addition of lanosterol did not restore
p35 expression to control levels (Figure 4a, second panel
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Figure 2 LanosterolrescuesdopaminergicneuronsinMPPþ-treatedventralmidbraincultures.Fluorescence imagesofprimaryventralmidbraincultures(DIV7)stained
with anti-TH, a marker for dopaminergic neurons. (a) Control cells (no treatment) and cells treated with 10mM MPPþ;( b) co-treated cells for 24h with 10mM MPPþ and
5mM of phosphatidylcholine (PC, left panel), lanosterol (middle panel) or cholesterol (right panel). Scale bars in (a) and (b) represent 200mm. (c) Plot of fold changesof each
treatment relative to control. y axis shows the average percentage of THþ neurons from each treatment condition divided by the average percentage of THþ neurons in
control. Error bars represent S.E.M. from four to ﬁve independent experiments. ***Po0.001 between lanosterol/MPPþ and MPPþ.( d) GC–MS proﬁles of lanosterol
(m/z 393, light grey) and the internal standard (deuterated b-sitosterol, m/z 493, black) in ventral midbrain culturesincubated for 24h with various lipid treatments.(e) Cellular
levels of sterol intermediates following various treatments normalized to control (no treatment). Fold changes plotted in y axis represent the levels of each metabolite in each
treatment condition normalized to control. Error bars represent S.E.M. from three independent experiments. ***Po0.001 between lanosterol treatment and control
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Cell Death and Differentiationfrom top). Consistent with previous ﬁndings implicating
glycogen synthase kinase 3 beta (Gsk-3b) (Ser9) phosphor-
ylation in PD pathogenesis,
22 we found increased phospho-
Gsk-3b in MPPþ-treated cells. However, this increase was
not affected by the addition of lanosterol (Figure 4a, third
panel from top).
Finally, we examined the levels of lanosterol synthase
(LSS), the enzyme that catalyzes cyclization of oxidosqua-
lene,the ratelimiting step in lanosterolsynthesis.
23 The levels
of LSS did not markedly change on MPPþ addition
(Figure 4a, fourth panel from top). Interestingly, however,
we observed a different localization pattern of LSS in MPPþ
-treated dopaminergic neurons. LSS immunostaining
appeared much more punctate after MPPþ treatment
(Figure 4b), suggesting drug-induced redistribution of LSS
toa differentintracellular compartment.We thusproceededto
examine the subcellular localization of LSS in control and
MPPþ-treated dopaminergic neurons.
Redistribution of LSS in dopaminergic neurons on
MPPþ insult. LSS is a membrane-associated enzyme,
which is targeted to the cytoplasmic leaﬂet of the
endoplasmic reticulum (ER).
24 Biochemical analysis of
puriﬁed fractions from mouse liver showed that the bulk of
LSS is indeed associated with the microsomal/ER fractions
and that minor amounts are found in puriﬁed mitochondria
(Figure 4c).
Consistent with our biochemical fractionation data, we
found that LSS colocalized with an ER marker (ER retention
sequence (lys-asp-glu-leu) (KDEL)) in both dopaminergic and
non-dopaminergic neurons (Figure 5a). Extensive overlap
between LSS and the ER marker was observed for both
dopaminergic and non-dopaminergic neurons (R
2¼0.83±
0.01 and 0.84±0.01, respectively). Less overlap was found
between LSS and translocase of outer mitochondrial mem-
brane 20 (TOMM20) (a mitochondrial marker) for both
dopaminergic and non-dopaminergic neurons (R
2¼0.70±
0.02 and 0.69±0.02, respectively, Figure 5a, second panel
from the top). This pattern changed noticeably in dopaminer-
gic neurons treated with MPPþ. The colocalization of LSS
with TOMM20 was markedly increased (R
2¼0.856±0.01,
Figure 5a, bottom last panel), with concomitant reduction in
the overlap of LSS with KDEL (R
2¼0.69±0.02, Figure 5a,
second panel from the bottom). Translocation of LSS from the
ER to mitochondria was also observed in dopaminergic
neurons co-treated with MPPþ and lanosterol (Figure 5b).
MPPþ did not, however, affect LSS localization in non-
dopaminergicneurons(Figure5b),consistentwiththeinability
of these cells to take up MPPþ. These data indicate that a
signiﬁcant fraction of LSS redistributes from the ER to
mitochondria in dopaminergic neurons exposed to MPPþ,
suggesting that LSS (and its product lanosterol) may have a
role in regulating mitochondrial function.
Lanosterol uncouples mitochondria in dopaminergic
neurons. An important aspect of mitochondrial physiology
can be assessed by measuring the mitochondrial membrane
potential (Dc), which is the electrical and chemical gradient
that drives protons across the inner membrane during
electron transport and oxidative phosphorylation. This
process is never completely ‘coupled’, allowing a fraction of
electrons and protons to be transported without concurrent
production of adenosine triphosphate (ATP). We ﬁrst
examined the impact of lanosterol on Dc in hippocampal
neurons using the ratiometric voltage-sensitive ﬂuorescent
dye, 5,50,6,60-tetrachloro-1,10,3,30-tetraethylbenzimidazolocarbo-
cyanine iodide (JC-1). Using time-lapse, multi-positioning
imaging to capture about 3–4 ﬁelds in 30-s intervals, we
measured changes of Dc on lipids addition by the ratiometric
analysis of JC-1 red to green emission. As expected,
treatment of neurons with 200nM m-chlorophenylhydrazone
(CCCP), a known uncoupler of oxidative phosphorylation,
induced an immediate and sharp reduction of the
mitochondrial membrane potential (B25% within 30s;
Figure 6a). Under these same experimental conditions,
exogenous addition of lanosterol reduced the membrane
potential by B20% over 15min, whereas PC and cholesterol
had no signiﬁcant effect (Figure 6b).
Werepeatedtheseexperimentsinventralmidbraincultures
(Figures 6c and d). As these cultures were grown at a lower
density than the hippocampal cultures, we needed to capture
10–15 ﬁelds in time-lapse multi-positioning imaging at lower
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Cell Death and Differentiationmagniﬁcation to gain enough statistical power. As a conse-
quence, this limited time intervals to 2min. We observed a
B20% of reduction in membrane potential on lanosterol
addition (Figures 6c and d), consistent with the results
obtained in hippocampal neurons.
As MPPþ uptake depends on ATP levels,
25 it is possible
that the addition of lanosterol causes mitochondrial depolar-
ization, and subsequently ATP depletion. This would, in turn,
inhibit MPPþ uptake in the mitochondria. To determine if
lanosterol alters ATP levels, we measured levels of ATP in
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Figure 5 LSS is redistributed from ER to mitochondria in dopaminergic neurons on addition of MPPþ.( a) Confocal images of ventral midbrain neurons stained with
TH (white), LSS (green), either KDEL (red, ﬁrst and third panels from the top) or TOMM20 (red, second and fourth panels from the top) of ventral midbrain neurons in control
andMPPþ treatment.Whiteboxesshowdopaminergic neuronsas determinedby THþ staining.Rightpanelsshowpixel intensitycorrelation plotsof LSSwith eitherKDEL
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2 values (a measure of colocalization) of two classes of neurons in control and MPPþ
-treated conditions. In control, R
2 values from co-staining of KDEL-LSS, n¼26 and n¼27, TOMM20-LSS, n¼20 and n¼21, were assessed for dopaminergic and non-
dopaminergic neurons respectively. In MPPþ-treated cells, R
2 values from co-staining of KDEL-LSS, n¼20 and n¼20, for TOMM20-LSS, n¼18 and n¼17, were
assessed for dopaminergic and non-dopaminergic neurons respectively. In MPPþ/lanosterol co-treated cells, R
2 values from co-staining of KDEL-LSS, n¼18 and n¼23,
for TOMM20-LSS, n¼19 and n¼18, were assessed for dopaminergic and non-dopaminergic neurons respectively. ****Po0.00001
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Cell Death and Differentiationneurons treated with PC, cholesterol or lanosterol. We did not
see any signiﬁcant changes in the levels of ATP across all
treatment conditions (Supplementary Figure S1), indicating
that lanosterol is unlikely to inhibit MPPþ uptake. Thus, one
mechanism by which lanosterol could mediate neuroprotec-
tion is through the uncoupling of mitochondria.
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Cell Death and DifferentiationLanosterol increases autophagy in dopaminergic
neurons. Previous studies have shown that the loss of
mitochondrial membrane potential can initiate the autophagic
degradation of damaged mitochondria.
26,27 Gene linked to
familial forms of PD, such as PINK1 and Parkin, are thought
to regulate this process, and PD-associated Parkin mutations
cause a decrease in mitophagy in mammalian cell lines.
28
We thus asked if lanosterol mediates autophagosome
formation in dopaminergic neurons. Using microtubule-
associated protein light chain 3 (LC3) as a marker for
autophagy, we quantiﬁed both the size and number of
autophagic vacuoles (AVs) in primary ventral midbrain
neurons on MPPþ/lanosterol treatment. Similar to other
studies,
29 we found that addition of MPPþ in primary
dopaminergic neurons increased the number of AVs by
about 2.5-fold (Figure 7). There is also about a 75% increase
in the average size of AVs with MPPþ treatment.
Remarkably, when neurons were exposed to lanosterol
alone, we observed a similar increase in AV size and
number. Co-treatment of MPPþ and lanosterol led to an
additive effect on autophagy, with signiﬁcant increases in
both the number and size of AVs, compared with MPPþ or
lanosterol alone (Figure 7).
Next, we addressed whether lanosterol has a speciﬁc effect
on axonal mitophagy. In PD, axons of dopaminergic neurons
progressively degenerate and ‘die back’, in a process that
may be accelerated by mitochondrial dysfunction and involve
mitophagy. For this, we grew hippocampal neurons in
microﬂuidic chambers to segregate axons from neuronal cell
bodies and dendrites.
30 Mitochondria were visualized by
expression of the ﬂuorescent reporter MitoRed and neurons
were immunostained for endogenous LC3. We found a small
but signiﬁcant increase in colocalization of MitoRed with LC3
(Figure 8) on lanosterol treatment, suggesting an increase in
axonal mitophagy. Taken together, these results suggest that
the protective effects of lanosterol are mediated by mitochon-
dria uncoupling, and subsequent clearance of damaged
mitochondria.
Discussion
The etiology of PD implicates several factors, including
mitochondrial dysfunction and misregulation of sterol meta-
bolism. Evidence implicating impaired mitochondrial function
in PD is substantial. This evidence is based on (1) the
identiﬁcation of rare PD-associated mutations in genes that
affect mitochondrial function such as the putative kinase,
PINK1 (PARK6), the E3 ligase Parkin (PARK2) and DJ-1
(PARK7); (2) similarities between PD and clinical symptoms
that arise on exposure to the neurotoxin MPTP, a complex I
inhibitor; and (3) a signiﬁcant decrease in complex I/II activity
in the platelets of patients with PD.
31
On the other hand, evidence for a role of aberrant sterol
metabolism in PD is rather controversial. For example, lower
levels of serum LDL-C are considered a risk factor for PD,
12,32
but it is unclear how serum LDL-C relates to levels of
cholesterol in the brain. Statins, which lower serum cholester-
ol levels by inhibiting 3-hydroxy-3-methyl-glutaryl-coenzyme
A reductase, have been used to treat PD, but there are many
unresolved questions regarding their beneﬁts (see review in
Becker and Meier
33).
In this study, we measured a selection of sterol metabolites
in the ventral midbrain and striatum of MPTP-treated mice,
two brain regions characterized by cell death and/or axonal
loss in both the MPTP model as well as in PD. Our results
show a highly selective reduction of lanosterol levels in these
affected areas (Figure 1) and point to an alteration of
lanosterol metabolism in MPTP-treated mice. We cannot
rule out the possibility that lanosterol is oxidized or metabo-
lized to di-hydrolanosterol or other products in MPTP-treated
animals because we are unable to measure these oxidized
metabolites.
Consistent with a role of lanosterol in PD pathogenesis,
we observed an improved survival of MPPþ-treated dopa-
minergic neurons on exogenous addition of lanosterol
(Figure 2). We also demonstrated that LSS relocalized from
the ER to mitochondria in dopaminergic neurons on MPPþ
treatment (Figures 4b and 5), suggesting an increase in
lanosterol synthesis in mitochondria. Interestingly, recent
lipidomic analysis of macrophages during stimulation with
Lipid A (a condition that leads to oxidative bursts) showed
a pronounced increase in lanosterol levels in several
intracellular compartments, including mitochondria,
16 impli-
catingthatmodulationoflanosterolmetabolismmaybepartof
a global cellular response to stress. If upregulation of
lanosterol synthesis is part of a cellular defense mechanism,
it is not clear why lanosterol levels drop in response to
MPTP treatment. In this regard, it is interesting to note that
two recent papers reported lowered lanosterol levels in the
serum of patients with Alzheimer’s disease,
34 and in
ﬁbroblasts challenged by virus infection.
35 One possible
explanation for these seemingly contradicting results is that
distinct types of stress differentially impact lanosterol meta-
bolism. Perhaps, in some cases, the substantial decrease in
lanosterol levels cannot be compensated by upregulation of
lanosterol synthesis as part of the cell’s protective response.
Alternatively, we cannot exclude the possibility that transloca-
tion of LSS to mitochondria in response to MPPþ is an
epiphenomenon, which is not indicative of a cellular response
to stress.
Our results, however, show that exogenous addition of
lanosterol leads to mild uncoupling of mitochondria in
dopaminergic and glutamatergic neurons, with no detectable
impact on ATP levels (Figure 6 and Supplementary Figure
Figure 6 Lanosterol inducesuncouplingof themitochondriaindopaminergicneurons.Liveimagingof JC-1 loaded neuronalcultures.(a) Controlplot showingchangesin
JC-1redtogreenratio,Df/f0,versustimeinhippocampalneuronstreatedwithCCCP,aknownuncoupler,n¼20.(b)PlotofDf/f0versustimeinhippocampalneuronstreated
with different lipids, n460 for each condition from three independent experiments. (c) Images of control and lanosterol-treated ventral midbrain cultures at the start of the
experiment (time¼0min, left panels) and the end of the experiment (time¼40min, middle panels). Right panels represent posteriori staining of TH for identiﬁcation of
dopaminergicneurons.WhiteboxesrepresentmagniﬁedTHþ neurons.Scalebarrepresents100mminmainﬁgureand10mm inmagniﬁedbox.(d)PlotofDf/f0versustime
for dopaminergic neurons, n410 for each condition from three independent experiments. In both types of cultures, lanosterol induces about 20% decrease in mitochondrial
membrane potential
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Cell Death and DifferentiationS1). The mitochondria uncoupling and protective effects of
lanosterol are strikingly similar to those observed with low
doseoftheuncoupler,FCCP,whichimprovescellularsurvival
in ischemic preconditioning but has no signiﬁcant impact on
ATP levels.
36 In the context of PD, the mitochondrial
uncoupling effect of lanosterol has important implications.
For example, Parkin is recruited to mitochondria via PINK1 on
membrane depolarization,
26 and regulates the clearance of
damaged mitochondria by mitophagy in mammalian cell
lines.
37 In addition, the translocation of Parkin to mitochondria
has etiological signiﬁcance, as a number of disease-
associated Parkin mutant proteins fail to translocate.
27,38
Together, these data point to a role of mitochondrial
uncoupling and autophagy in PD pathogenesis. In line with
this model, our results reveal that lanosterol induces
mitochondrial uncoupling (Figure 6) and promotes autophagy
(Figures 7 and 8).
Although mitochondrial uncoupling has been shown to be
neuroprotective in various models, including MPTP-induced
neurodegeneration,
7–9 the mechanisms involved are still
unclear. Some studies have shown that uncoupling reduces
superoxide species, offering an explanation for improved
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Figure7 LanosterolandMPPþ increasethenumberofAVsindopaminergicneurons.(a)ConfocalimagesofventralmidbrainneuronsstainedwithTH(toppanels),LC3
(middle panels) and AV quantiﬁcation (ImageJ software output, bottom panels) with various treatment conditions indicated on the top. Scale bar represents 10mm.
(b) Graphical plot showing the average number of AV identiﬁed per THþ cells and the average size of AV in pixel area during treatment with various lipids and MPPþ
co-treatment. For each condition, n440 THþ cells from three independent experiments. Error bars represent S.E.M. ***Po0.001
Lanosterol protects dopaminergic neurons
L Lim et al
424
Cell Death and Differentiationneuronal survival in the MPTP model, because oxidative
stress is thought to be the primary cause of cell death.
8,9 In
other studies, transient mitochondrial uncoupling is neuropro-
tective in glutamate-induced neurotoxicity, as it prevents
uptakeofcalciumfromthecytosoltomitochondria.
11Finally,a
recent study showed that DJ-1, a gene involved in early onset
PD, regulates the expression of two UCPs (UCP4 and UCP5)
and controls oxidative stress in mitochondria of dopaminergic
neurons in the substantia nigra.
10 Although these studies
cited above have identiﬁed different modulators by which a
cell/neuron alters mitochondrial membrane potential, they are
in good agreement with our ﬁndings, whereby uncoupling
mechanism proves to be a central regulator of cellular
response to stress.
In conclusion, we report that in addition to its role as a
precursor for cholesterol biosynthesis, lanosterol acts as a
survival factor for dopaminergic neurons. Furthermore, our
ﬁndings point to an unexpected role of this sterol metabolite in
regulating mitochondrial function and autophagy, and bring
sterol metabolism to the forefront of neurobiological disease.
Materials and Methods
PD animal model: MPTP injections. All procedures performed in rodents
were in accordance with IACUC guidelines. MPTP injections were performed
according to previously published methods, following the acute schedule.
17 Brieﬂy,
C57B6 mice were given four i.p. doses of either 18mg/kg of MPTP (Sigma-Aldrich,
St. Louis, MO, USA) or saline (control) every 2h. Mice were decapitated 48h after
thelastdose,andtheventralmidbrainandstriatumweredissectedandsnap-frozen
for subsequent lipid extraction and GC–MS analysis. Previously published data
using the same protocol showed that at this timepoint, about 35% of dopaminergic
neurons have degenerated.
17
Lipid standards and liposomes. Lanosterol, cholesterol, 1,2-dimyristoyl-
sn-glycero-3-phosphocholine (DMPC or PC) and desmosterol-d6 (all of highest
purity, 499%) were purchased from Avanti Polar Lipids (Alabaster, AL, USA).
Oxysterol standards a-cholestane, 7a-hydroxycholesterol, 7b-hydroxycholesterol,
7-dehydrocholesterol, 25-hydroxycholesterol and 7-ketocholesterol were
obtained from Sigma (St. Louis, MO, USA). 7a-Hydroxycholesterol-d7,
7b-hydroxycholesterol-d7, b-sitosterol-d7, campesterol-d3, lathosterol-d4 and
7-ketocholesterol-d7 were purchased from CDN Isotopes (Quebec, Canada).
27-Hydoxycholesterol-d5, 24-hydroxycholesterol and 24-hydroxycholesterol-d7
were purchased from Medical Isotopes (Pelham, AL, USA). Deuterated
standards obtained were of 495% purity.
Lanosterol, cholesterol and PC were dissolved in chloroform/methanol (1:1).
Cholesterol or lanosterol was mixed in equimolar proportion with PC and dried by
vacuum in a Speedvac (Thermosavant, Waltham, MA, USA). The lanosterol/PC or
cholesterol/PCmixture was resuspendedin culturemedium on the day of treatment
to make a 0.5mM stock liposome. Each type of stock liposome was used in the
neuronal cultures within a day of preparation.
Lipidextraction. Fortissuesandcells,extractionoflipidswasperformedusing
Bligh and Dyer method.
39 Brieﬂy, cells were washed 3–5 times with phosphate-
buffered saline (PBS), scraped in 400ml ice-cold methanol and transferred to a
1.5-mlEppendorftube.Chloroform(200ml)wasaddedandsampleswerevortexfor
1min. Next, 300ml of 1M KCL was added, and the homogenates were
microcentrifuged at 14000r.p.m. for 5min at 41C to separate phases. The lower
organic phase was carefully transferred to a new Eppendorf tube. The aqueous
phase was re-extracted twice with 300ml chloroform. All organic phases were
pooled and dried under vacuum using a Speedvac and stored at  801C until
derivatization and subsequent GC–MS analysis.
Ventral midbrain (B20–25mg) and striatum (B15–20mg) were dissected and
tissues were homogenized using a Dounce homogenizer in 600ml ice-cold
chloroform/methanol (1:2). Another 300ml chloroform was added to the
homogenate followed by the addition of 450ml of 1M KCL. The homogenates
were microcentrifuged at 14000r.p.m. for 5min at 41C. The lower organic phase
was carefully transferred to a new Eppendorf tube, and the aqueous phase was re-
extracted twice with 300ml chloroform. All organic phases were pooled and dried
under vacuum in a Speedvac. Dried samples were then stored at  801C until
derivatization and subsequent analyses.
Sample preparation for GC–MS. Brieﬂy, dried lipid extracts were
resuspended in chloroform/methanol (1:1) to a concentration of 0.1mg tissue/ml
solvent.A20-ml sampleoflipidextractwasremovedandcompletelydriedinaglass
vial. For each sample, we added a mixture of heavy isotopes: 40ng of
7a-hydroxycholesterol-d7,4 0 n go f7 b-hydroxycholesterol-d7, 40ng of 26(27)-
hydroxycholesterol-d5, 80ng of 7-ketocholesterol-d7, 0.2mgo f5 a-cholestane,
0.2mg of desmosterol-d6, 0.2mg of lathosterol-d4, 0.2mg of campesterol-d7 and
0.2mgo fb-sitosterol-d7 in 25ml of ethanol. Standards and sample mixtures were
dried under a stream of N2 before adding the derivatizing agent (15ml acetonitrile
and 15ml BSTFA þ TMCS; Pierce Thermoscientiﬁc, Waltham, MA, USA). The
derivatized samples were analyzed with an Agilent 5975 inert XL mass selective
detector (Santa Clara, CA, USA). Selective ion monitoring was performed using the
electron ionization mode at 70eV (with the ion source maintainedat 2301C and the
quadrupoleat1501C)tomonitoronetargetion.Twoqualiﬁerionswereselectedfor
the mass spectrum of each compound to optimize for sensitivity and speciﬁcity.
Ventralmidbraincultures. Ventralmidbrainsfrom20postnatalday0today
2 rodents were dissected and digested in papain solution and plated on a glia layer.
Cells were cultured in serum-free neurobasal/B27 medium (Invitrogen, Carlsbad,
CA, USA) supplemented with superoxide dismutase 1 (5mg/ml), apo-transferrin
(95mg/ml)andinsulin(21mg/ml)(allfromSigma).IncontrasttoRayportetal.,
40our
control lanosterol
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Figure 8 Lanosterol increases mitophagy in axons. (a) Confocal images of hippocamal axons stained with LC3 (top panels, green) and electroporated with MitoRed
(middle panels, red). Bottom panels show of LC3 and MitoRed. White arrows represent-colocalization of the two channels. Scale bar represents 20mm. (b) Graphical plot of
average percentage of mitochondria with LC3-positive stains. Error bars represent S.E.M. For each condition, n440 axons were assessed from three independent
experiments. *Po0.05
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Cell Death and Differentiationculture medium contained no serum because the cultures were subjected to lipid
additioninexperimentalconditions.Onehourafterplatingthecells,10ng/mlofglial-
derived neurotrophic factor (Millipore, Billerica, MA, USA) was added. To inhibit glia
growth, a solution of 16.5mg/ml uridine and 6.7mg/ml 5-ﬂuorodeoxyuridine was
added 1 day after plating. Cells were then cultured for 7 days (days in vitro (DIV)7)
before treatment with MPPþ and various types of liposome.
Hippocampal neuron cultures. Hippocampal neurons from rats E18.5
embryos were cultured in neurobasal/B27 as described.
19 Brieﬂy, neurons were
plated on a wax-dotted coverslip coated with 1mg/ml of poly-D-lysine (Sigma). Two
hours after plating, when neurons had attached, the coverslips were ﬂipped into a
six-well plate containing a glia feeder layer. PC, cholesterol or lanosterol liposome
(5mm each) was added after DIV7.
Western and antibodies. For western blots, cultured cells were washed
three times with 1 PBS. Cells were lysed in 100ml of RIPA buffer (50mM Tris-
HCl, pH 7.4, 1% NP-40, 0.25% Na-deoxycholate, 150mM NaCl and 1mM EDTA),
supplemented with a cocktailof proteaseinhibitors (CompleteMini-EDTA inhibitors,
Roche Diagnostics, Indianapolis, IN, USA). In all, 20mg of cell protein lysate was
loaded in each well of a 10% polyacrylamide gel containing 0.1% SDS. After
electrophoresis, proteins were transferred to nitrocellulose membrane and probed
with the following antibodies: (i) rabbit anti-p35 (C19; 1:1000, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), (ii) rabbit anti-LSS (1:1000, AVIA, Systems
Biology, San Diego, CA, USA), (iii) rabbit anti-tyrosine hydroxylase (TH) (1:20000,
Covance, Princeton, NJ, USA), (iv) rabbit anti-SREBP2 (1:1000, Abcam,
Cambridge, MA, USA), (v) rabbit anti-calnexin (1:2000, Abcam), (vi) rabbit anti-
VDAC/porin (1:2000, Abcam) and (vii) rabbit anti-pGSK-3a/b (ser21/9) 1:1000,
Cell Signaling, Danvers, MA, USA). Peroxidase-conjugated anti-rabbit or anti-
mouse secondary antibodies (1:10000) were purchased from Bio-Rad (Hercules,
CA, USA). Immunoblots were visualized with enhance chemiluminescence reagent
from Pierce Thermoscientiﬁc.
Fluorescence microscopy and quantiﬁcation of dopaminergic
neuronalsurvival. Ventralmidbrainculturesplatedon12-mmcoverslipswere
treated for 24h with 10mM MPPþ with or without 5mM PC, 5mM cholesterol or
5mM lanosterol liposome. Cells were washed three times with PBS, then ﬁxed with
4% paraformaldehyde for 20min, followed by permeabilization and blocking in 5%
fetalbovineserumin0.1%TritonX-100for30min.Cellswerethenstainedwithanti-
TH (secondary: Alexa-ﬂuor 488, green) and neuron-speciﬁc class III beta tubulin
(TUJ1)(secondary:Alexa-ﬂuor555,red).Anti-mouseandanti-rabbitAlexa-ﬂuor488
and 555 (1:1000) were purchase from Molecular Probes (Eugene, OR, USA)/
Invitrogen. TUJ1-positive and TH-positive cells were counted with an Olympus
ﬂuorescence microscope (Tokyo, Japan) with FITC and TRITC ﬁlter sets. Every
neuron on the 12-mm coverslip was counted. The percentage of dopaminergic
neurons in each group was determined by the number of THþ/TUJ1þ cells.
Typically, in each control coverslip, there were 2000–3000 TUJ1þ cells, of which
400–1200 were THþ. For each treatment, we assessed 4–6 coverslips per
independentexperiment. Theaveragesof 4–5 independentexperiments are shown
in the ﬁgures.
Confocal microscopy and colocalization studies. Ventral midbrain
cultures in control and MPPþ-treated cells were stained with rabbit anti-LSS
(1:100), monoclonal mouse anti-TOMM20 (1:500) (Abcam) or monoclonal mouse
anti-KDEL (1:500) (Abcam), and sheep anti-TH (1:500) (Abcam). The secondary
antibodies, goat anti-mouse Alexa-ﬂuor 555, goat anti-rabbit Alexa-ﬂuor 488 and
donkey anti-sheep Alexa-ﬂuor 633, were obtained from Invitrogen. Cells were
imaged with a laser-scanning confocal microscope (LSM510, Carl Zeiss,
Oberkochen, Germany) with excitation and emission ﬁlters meeting the
secondary Alexa-ﬂuor antibody dye speciﬁcations. Images were taken using a
63X objective. To quantify colocalization, we plotted the pixel intensities of LSS
versus KDEL or TOMM20 from regions of interest (ROIs) drawn around single
neurons (either TH-positive or -negative), and calculated the linear regression
coefﬁcient, R
2, for 16–22 individual ROI/neuron.
Live-cell confocal imaging and measurement of mitochondrial
membrane potential. Mitochondrial membrane potential was measured in
live neurons using JC-1. All live-imaging experiments were conducted in cell
medium, (371C and 5% CO2) with a spinning disk confocal microscope, equipped
with a Cool SNAP HQ2 CCD camera (Photometrics, Tucson, AZ, USA), a fully
automated stage and built in autofocusing system (PFS, Nikon, Tokyo, Japan) and
driven by Metamorph 7.6 (Universal Imaging, Ypsilanti, MI, USA). JC-1 is excited at
488-nm, and its ﬂuorescence emission was collected at 530±10nm (green) and
590±17nm (red), corresponding to peak ﬂuorescence from the monomer and
aggregate signals, respectively. Mitochondrial membrane potential was measured
by taking the red to green emission ratio.
For ventral midbrain cultures (DIV7), cells were seeded at 50 cells/mm
2 in a
glass-bottom labtek well. Cells were loaded with 1mg/ml JC-1 (Invitrogen) in culture
medium, and were incubated for 30min at 371C, washed twice with HBSS and
imaged in conditioned culture medium. Multi-position time-lapse imaging of 10–15
randomly chosen ﬁelds was performed at 2-min interval over 40min. At the end of
the experiment, ventral midbrain cells were ﬁxed on stage for 20min with 4% PFA
and stained for TH with a secondary antibody coupled to Alexaﬂuro-568 (red) and
DAPI.TheretrospectivestainingofTHallowedfortheidentiﬁcationofdopaminergic
neurons, which were the only ones included in the analyses. Hippocampal cultures
were plated at a higher density (300 cells/mm
2), and multi-position time-lapse
imaging of 3–4 ﬁelds was performed at 30-s intervals for 20min.
For both types of cultures, the intensity of the JC-1 red-to-green ratio was
measured in each frame, and the change in mitochondrial membrane potential was
plotted as Df/f0, where f0 is the average JC-1 red-to-green ratio over the ﬁrst 10
frames before treatment. Decay curves were ﬁtted to a mono-exponential function,
y¼x0e
 t/t, using IGOR Pro 6.1 (WaveMetrics Inc., Lake Oswego, OR, USA).
Measurement of CoQ. For each condition, 3 to 4 million hippocampal
neurons (DIV7) were treated with various lipids and incubated for 24h. Cells were
washed two times with cold PBS and scraped in 0.5ml of cold PBS. Cells were
centrifuged at 1000 g to pellet the cells, and resuspended in 100ml fresh PBS.
Next, 750ml of hexane/ethanol (5:2 v/v) was added, and samples were vigorously
vortexed for 1min. To extract CoQ, 400ml of the organic phase was collected and
completely dried under a stream of N2, followed by LC–MS analysis.
An Agilent HPLC 1200 system coupled with an Applied Biosystems 3200 QTrap
mass spectrometer (Foster City, CA, USA) was used for measuring CoQ8, Q9, and
Q10 and free cholesterol. Chromatographic separation was carried out using an
Agilent Zorbax Eclipse XDB-C18 column (i.d. 4.6 150mm). High-pressure liquid
chromatography (HPLC) conditions were as the following: mobile phase:
chloroform/methanol 1:1 (v/v); ﬂow rate: 0.5ml/min; column temperature: 301C;
injection volume: 10ml. The LC–MS instrument was operated in positive
atmospheric pressure chemical ionization mode with a vaporizer temperature of
5001C and a corona current of 3mA. CoQ6 was used as an internal standard and
monitored with an multiple reaction monitoring (MRM) transition of 591.4197.0.
MRMtransitionsof727.5197.0,795.5197.0and863.6197.0weresetupforanalysis
of CoQ8, Q9 and Q10, respectively.
Quantiﬁcation of AVs. Ventral midbrain cultures plated on 12-mm coverslips
were treatedfor 24h with 10mM MPPþ with or without 5mM PC, 5mM cholesterol
or 5mM lanosterol. Cells were washed three times with PBS, then ﬁxed with 4%
paraformaldehyde for 20min and permeabilized with 100mg/ml of digitonin for
10min. Following permeabilization, cells were washed three times with PBS and
stained with anti-TH (secondary: Alexa-ﬂuor 488, green) and anti-LC3 (1:100,
mouse monoclonal, MBL cat. no.: 152–3A, secondary: Alexa-ﬂuor 555, red). To
quantify AV in dopaminergic neurons, THþ cell soma were imaged with a laser-
scanning confocal microscope (LSM510, Carl Zeiss) with excitation and emission
ﬁlters meeting the secondary Alexa-ﬂuor antibody dye speciﬁcations. Images were
taken using a 63X objective with the same laser power and gain. The 12-bit images
were quantiﬁed using ImageJ (analyze particle drop-in, National Institute of Health,
Bethesda, MD,USA). For eachimage,detectedLC3punctawereintensitythresholded
(o1000) and gated for size (o15 pixel). For each condition, 40–60 THþ cells were
assessed from three independent experiments.
As a positive control for our method of evaluating AV, mouse embryonic
ﬁbroblast grown in serum or serum deprived were stained with LC3 and quantiﬁed
according to the same parameters. As expected and shown in supplementary data
(Supplementary Figure S2), there is approximately a 25-fold increase in AV on
serum starvation.
Quantiﬁcation of mitophagy in axons. E18.5 hippocampal neurons
were electroporated using the Amaxa poration system (Lonza, Basel, Switzerland)
with MitoRed construct (Clonetech, Mountain View, CA, USA, cat. No.: PT-3633-5).
Cells were then plated in microﬂuidic chambers (Xona Microﬂuidics, Temecula, CA,
USA), which allow for physical separation of axons and cell somas. At DIV7,
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Cell Death and Differentiationneuronswere treatedwith 5mM PC, 5mM cholesterol,5mM lanosterolor 200nM of
rapamycin (positive control) for 24h. Cells were then ﬁxed with 4%
paraformaldehyde for 20min and permeabilized with 100mg/ml of digitonin for
10min. Following permeabilization, cells were washed three times with PBS, and
stained with anti-LC3 (secondary: Alexa-ﬂuor 488, green). To quantify mitophagy,
the percentage of MitoRed and LC3-positive mitochondria were plotted as a
percentage to total MitoRed-positive mitochondria using the Metamorph 7.6
colocalization drop-in. For each condition, images of 40–50 axons were taken from
three independent experiments.
Statistical analyses. Error bars represent S.E.M. For fold changes in sterol
intermediates, P-values were calculated with two-tailed Mann–Whitney U-test. For
in vitro assessment of dopaminergic neuron survival, CoQ levels, ATP levels, AV
number and size, percentage of mitophagy, P-values were calculated with
two-tailed Student’s t-test.
Conﬂict of Interest
The authors declare no conﬂict of interest.
Acknowledgements. WethankThiloHagenforprovidinguswithanaliquotof
CCCP. This study was supported by the National University of Singapore (NUS),
Department of Biological Sciences fellowship, the Singapore Biomedical Research
Council (BMRC) Grant ID 08/1/21/19/558, the Singapore National Research
FoundationunderCRPAwardNo.2007-04andtheSystemsX.chRTDprojectLipidX.
1. Lesage S, Brice A. Parkinson’s disease: from monogenic forms to genetic susceptibility
factors. Hum Mol Genet 2009; 18 (R1): R48–R59.
2. Dauer W,PrzedborskiS.Parkinson’s disease:mechanisms and models. Neuron 2003;39:
889–909.
3. CooksonMR.DJ-1, PINK1,and their effects onmitochondrialpathways. MovDisord 2010;
25(Suppl 1): S44–S48.
4. Keeney PM, Xie J, Capaldi RA, Bennett Jr JP. Parkinson’s disease brain mitochondrial
complex I has oxidatively damaged subunits and is functionally impaired and
misassembled. J Neurosci 2006; 26: 5256–5264.
5. Liu Y, Yang H. Environmental toxins and alpha-synuclein in Parkinson’s disease. Mol
Neurobiol 2005; 31: 273–282.
6. Virmani A, Gaetani F, Binienda Z. Effects of metabolic modiﬁers such as carnitines,
coenzyme Q10, and PUFAs against different forms of neurotoxic insults:
metabolic inhibitors, MPTP, and methamphetamine. Ann NY Acad Sci 2005; 1053:
183–191.
7. Horvath TL, Diano S, Leranth C, Garcia-Segura LM, Cowley MA, Shanabrough M et al.
Coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss in a
primate model of Parkinson’s disease. Endocrinology 2003; 144: 2757–2760.
8. Andrews ZB, Horvath B, Barnstable CJ, Elsworth J, Yang L, Beal MF et al. Uncoupling
protein-2 is critical for nigral dopamine cell survival in a mouse model of Parkinson’s
disease. J Neurosci 2005; 25: 184–191.
9. Conti B, Sugama S, Lucero J, Winsky-Sommerer R, Wirz SA, Maher P et al. Uncoupling
protein 2 protects dopaminergic neurons from acute 1,2,3,6-methyl-phenyl-
tetrahydropyridine toxicity. J Neurochem 2005; 93: 493–501.
10. Guzman JN, Sanchez-Padilla J, Wokosin D, Kondapalli J, Ilijic E, Schumacker PT et al.
Oxidant stress evoked by pace making in dopaminergic neurons is attenuated by
DJ-1. Nature 2010; 468: 696–700.
11. Stout AK, Raphael HM, Kanterewicz BI, Klann E, Reynolds IJ. Glutamate-induced neuron
death requires mitochondrial calcium uptake. Nat Neurosci 1998; 1: 366–373.
12. Huang X, Chen H, Miller WC, Mailman RB, Woodard JL, Chen PC et al. Lower low-density
lipoprotein cholesterol levels are associated with Parkinson’s disease. Mov Disord 2007;
22: 377–381.
13. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum cholesterol levels and the riskof
Parkinson’s disease. Am J Epidemiol 2006; 164: 998–1002.
14. Broersen K, Brink D, Fraser G, Goedert M, Davletov B. Alpha-synuclein adopts an alpha-
helical conformation in the presence of polyunsaturated fatty acids to hinder Micelle
formation. Biochemistry 2006; 45: 15610–15616.
15. BoscoDA,FowlerDM,ZhangQ,Nieva J,PowersET,WentworthJrPetal.Elevatedlevels
ofoxidizedcholesterolmetabolitesinLewybodydiseasebrainsacceleratealpha-synuclein
ﬁbrilization. Nat Chem Biol 2006; 2: 249–253.
16. Andreyev AY, Fahy E, Guan Z, Kelly S, Li X, McDonald JG et al. Subcellular organelle
lipidomics in TLR-4-activated macrophages. J Lipid Res 2010; 51: 2785–2797.
17. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S. Time course and morphology of
dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine. Neurodegeneration 1995; 4: 257–269.
18. Vance JE, Hayashi H, Karten B. Cholesterol homeostasis in neurons and glial cells. Semin
Cell Dev Biol 2005; 16: 193–212.
19. Kaech S, Banker G. Culturing hippocampal neurons. Nat Protoc 2006; 1: 2406–2415.
20. Fernandez A, Llacuna L, Fernandez-Checa JC, Colell A. Mitochondrial cholesterol loading
exacerbates amyloid beta peptide-induced inﬂammation and neurotoxicity. J Neurosci
2009; 29: 6394–6405.
21. Neystat M, Rzhetskaya M, Oo TF, Kholodilov N, Yarygina O, Wilson A et al. Expression of
cyclin-dependent kinase 5 and its activator p35 in models of induced apoptotic death in
neurons of the substantia nigra in vivo. J Neurochem 2001; 77: 1611–1625.
22. Garcia-Gorostiaga I, Sanchez-Juan P, Mateo I, Rodriguez-Rodriguez E, Sanchez-
Quintana C, del Olmo SC et al. Glycogen synthase kinase-3 beta and tau genes interact in
Parkinson’s and Alzheimer’s diseases. Ann Neurol 2009; 65: 759–761 author reply
761-752.
23. Mori M, Sawashita J, Higuchi K. Functional polymorphisms of the LSS and Fdft1 genes in
laboratory rats. Exp Anim 2007; 56: 93–101.
24. Yamamoto S, Lin K, Bloch K. Some properties of the microsomal 2,3-oxidosqualene sterol
cyclase. Proc Natl Acad Sci U S A 1969; 63: 110–117.
25. Ramsay RR, Singer TP. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the
neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria.
J Biologic Chem 1986; 261: 7585–7587.
26. Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is recruited selectively to impaired
mitochondria and promotes their autophagy. J Cell Biol 2008; 183: 795–803.
27. Matsuda N, Sato S, Shiba K, Okatsu K, Saisho K, Gautier CA et al. PINK1 stabilized by
mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent
Parkin for mitophagy. J Cell Biol 2010; 189: 211–221.
28. GeislerS,HolmstromKM,TreisA,SkujatD,WeberSS,FieselFCetal.ThePINK1/Parkin-
mediated mitophagy is compromised by PD-associated mutations. Autophagy 2010; 6:
871–878.
29. Cherra 3rd SJ, Kulich SM, Uechi G, Balasubramani M, Mountzouris J, Day BW et al.
Regulation ofthe autophagy protein LC3 by phosphorylation. J Cell Biol 2010;190: 533–539.
30. Park JW, Kim HJ, Byun JH, Ryu HR, Jeon NL. Novel microﬂuidic platform for culturing
neurons:culturing andbiochemicalanalysisofneuronalcomponents.BiotechnolJ2009;4:
1573–1577.
31. Haas RH, Nasirian F, Nakano K, Ward D, Pay M, Hill R et al. Low platelet mitochondrial
complex I and complex II/III activity in early untreated Parkinson’s disease. Ann Neurol
1995; 37: 714–722.
32. Huang X, Abbott RD, Petrovitch H, Mailman RB, Ross GW. Low LDL cholesterol and
increased risk of Parkinson’s disease: prospective results from Honolulu-Asia Aging Study.
Mov Disord 2008; 23: 1013–1018.
33. Becker C, Meier CR. Statins and the risk of Parkinson disease: an update on the
controversy. Expert Opin Drug Saf 2009; 8: 261–271.
34. Kolsch H, Heun R, Jessen F, Popp J, Hentschel F, Maier W et al. Alterations of cholesterol
precursorlevelsinAlzheimer’sdisease.Biochimica etbiophysicaacta2011;1801: 945–950.
35. Blanc M, Hsieh WY, Robertson KA, Watterson S, Shui G, Lacaze P et al. Host defense
against viral infection involves interferon mediated down-regulation of sterol biosynthesis.
PLoS Biol 2011; 9: e1000598.
36. Brennan JP, Southworth R, Medina RA, Davidson SM, Duchen MR, Shattock MJ.
Mitochondrial uncoupling, with low concentration FCCP, induces ROS-dependent
cardioprotectionindependentofKATPchannelactivation.CardiovascRes2006;72:313–321.
37. GeislerS,HolmstromKM,SkujatD,FieselFC,RothfussOC,KahlePJetal.PINK1/Parkin-
mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol 2010; 12:
119–131.
38. Okatsu K, Saisho K, Shimanuki M, Nakada K, Shitara H, Sou YS et al. p62/SQSTM1
cooperates with Parkin for perinuclear clustering of depolarized mitochondria. Genes Cells
2010; 15: 887–900.
39. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and puriﬁcation. Can J Biochem
Physiol 1959; 37: 911–917.
40. Rayport S, Sulzer D, Shi WX, Sawasdikosol S, Monaco J, Batson D et al. Identiﬁed
postnatal mesolimbic dopamine neurons in culture: morphology and electrophysiology.
J Neurosci 1992; 12: 4264–4280.
This work is licensed under the Creative Commons
Attribution-NonCommercial-No Derivative Works 3.0
Unported License. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-nd/3.0
Supplementary Information accompanies the paper on Cell Death and Differentiation website (http://www.nature.com/cdd)
Lanosterol protects dopaminergic neurons
LL i met al
427
Cell Death and Differentiation